Publicações

Long-Term Real-World Effectiveness and Safety of Fremanezumab in 1140 Patients with Migraine and at Least 6 Months of Treatment: Third Interim Analysis of the Pan-European Pearl Study

AuthID
P-01A-8SY

Author(s)

Ashina, M

Mitsikostas, DD

Amin, FM

Kokturk, P

Schankin, CJ

Sahin, G

Pozo-Rosich, P

Dorman, PJ

Nezádal, T

Poole, AC

Martins, IP

Sumelahti, ML

Campos, VR

Ahn, AH

Akcicek, H

Tassorelli, C

Tipo de Documento

Article in Press

Year published

2025

Publicado

in NEUROLOGICAL SCIENCES, ISSN: 1590-1874

Volume: 46, Número: 12, Páginas: 6907-6921 (15)

Indexing

Wos^®

Scopus^®

Crossref^®

Pubmed^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1007/s10072-025-08484-1

Pubmed: 41032235

SCOPUS: 2-s2.0-105018198667

Wos: WOS:001585031300001

Source Identifiers

ISSN: 1590-1874

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Long-Term Real-World Effectiveness and Safety of Fremanezumab in 1140 Patients with Migraine and at Least 6 Months of Treatment: Third Interim Analysis of the Pan-European Pearl Study

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Long-Term Real-World Effectiveness and Safety of Fremanezumab in 1140 Patients with Migraine and at Least 6 Months of Treatment: Third Interim Analysis of the Pan-European Pearl Study

Links Úteis

Ajuda